share_log

Earnings are growing at Kangji Medical Holdings (HKG:9997) but shareholders still don't like its prospects

Earnings are growing at Kangji Medical Holdings (HKG:9997) but shareholders still don't like its prospects

康基醫療控股(HKG:9997)盈利增長,但股東仍不看好其前景
Simply Wall St ·  2022/05/29 21:00

It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Investors in Kangji Medical Holdings Limited (HKG:9997) have tasted that bitter downside in the last year, as the share price dropped 51%. That's well below the market decline of 23%. Because Kangji Medical Holdings hasn't been listed for many years, the market is still learning about how the business performs. Furthermore, it's down 20% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 8.6% decline in the broader market, throughout the period.

購買指數基金很容易達到與整體市場回報相匹配的水平。積極投資者的目標是買入表現遠遠好於大盤的股票--但在這個過程中,他們面臨表現不佳的風險。投資者在康基醫療控股有限公司(HKG:9997)去年股價下跌了51%,嚐到了苦澀的苦果。這遠低於23%的市場跌幅。由於康吉醫療控股已經多年未上市,市場仍在瞭解該業務的表現。此外,它在大約四分之一的時間裏下跌了20%。對於持有者來説,這並不是什麼樂趣。當然,在此期間,這一股價走勢很可能受到大盤8.6%跌幅的影響。

With the stock having lost 8.1% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.

鑑於該公司股價在過去一週下跌了8.1%,我們有必要看看它的業務表現,看看是否有任何危險信號。

Check out our latest analysis for Kangji Medical Holdings

查看我們對康吉醫療控股公司的最新分析

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

雖然有效市場假説繼續被一些人傳授,但事實證明,市場是過度反應的動態系統,投資者並不總是理性的。評估圍繞一家公司的情緒變化的一個有缺陷但合理的方法是將每股收益(EPS)與股價進行比較。

Even though the Kangji Medical Holdings share price is down over the year, its EPS actually improved. It could be that the share price was previously over-hyped.

儘管康吉醫療控股的股價在過去一年裏有所下降,但其每股收益實際上有所改善。可能是股價之前被過度炒作了。

It's fair to say that the share price does not seem to be reflecting the EPS growth. But we might find some different metrics explain the share price movements better.

公平地説,股價似乎並沒有反映出每股收益的增長。但我們可能會發現一些不同的衡量標準可以更好地解釋股價走勢。

Kangji Medical Holdings managed to grow revenue over the last year, which is usually a real positive. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.

康吉醫療控股去年實現了營收增長,這通常是一個真正的利好消息。由於基本面指標不能很好地解釋股價下跌,如果市場反應過度,可能會有機會。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

該公司的收入和收益(隨着時間的推移)如下圖所示(點擊查看具體數字)。

SEHK:9997 Earnings and Revenue Growth May 30th 2022
聯交所:9997盈利及收入增長2022年5月30日

We know that Kangji Medical Holdings has improved its bottom line lately, but what does the future have in store? If you are thinking of buying or selling Kangji Medical Holdings stock, you should check out this free report showing analyst profit forecasts.

我們知道康吉醫療控股最近提高了利潤,但未來會是什麼樣子呢?如果你正在考慮購買或出售康基醫療控股的股票,你應該看看這個免費顯示分析師利潤預測的報告。

A Different Perspective

不同的視角

Kangji Medical Holdings shareholders are down 50% for the year (even including dividends), even worse than the market loss of 23%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. With the stock down 20% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Basically, most investors should be wary of buying into a poor-performing stock, unless the business itself has clearly improved. It's always interesting to track share price performance over the longer term. But to understand Kangji Medical Holdings better, we need to consider many other factors. Even so, be aware that Kangji Medical Holdings is showing 2 warning signs in our investment analysis , and 1 of those makes us a bit uncomfortable...

康基醫療控股的股東全年下跌50%(即使包括股息),甚至比市場23%的損失還要糟糕。這令人失望,但值得記住的是,整個市場的拋售不會有任何幫助。過去三個月,該公司股價下跌了20%,市場似乎並不認為該公司已經解決了所有問題。基本上,大多數投資者應該對買入表現不佳的股票保持警惕,除非業務本身已經明顯改善。跟蹤股價的長期表現總是很有趣的。但要更好地理解康基醫療控股,我們還需要考慮許多其他因素。即便如此,請注意,康基醫療控股公司正在展示我們的投資分析中的2個警告信號,其中一條讓我們有點不舒服...

We will like Kangji Medical Holdings better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我們看到一些大的內部收購,我們會更喜歡康基醫療控股。在我們等待的時候,看看這個免費最近有大量內幕收購的成長型公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.

請注意,本文引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論